MDS Trials

Luspatercept granted FDA approval as a first-line treatment for anemia in patients with lower-risk MDS

On August 28, luspatercept-aamt, a first-in-class erythroid-maturation agent, was approved by the...

Luspatercept for ESA-naïve TD patients with LR-MDS: Interim analysis from the COMMANDS study

Here, we summarize an interim analysis from the COMMANDS trial recently published by Platzbecker, et al. in...

Imetelstat in patients with lower-risk MDS: Updates from the IMerge trial

At ASCO 2023 and EHA 2023, updates were presented on the efficacy and safety of imetelstat, including disease-modifying...

Imetelstat for patients with highly transfusion-dependent MDS

The initial treatment option for patients with lower-risk MDS is the use of erythropoiesis-stimulating agents (ESAs) with/without other...

Quality of life assessment and transfusion-free survival

During the MDS Hub Steering Committee meeting held on May 11, 2023, Theo de Witte chaired a discussion on quality of life assessment and...

Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS

To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...

HRQoL and vulnerability analysis from the National MDS Natural History Study

The National MDS Natural History Study is a prospective initiative, enrolling patients with cytopenia to be assessed for...

The utility of targeted exon sequencing in the diagnosis of MDS in people with cytopenia

We summarize results from the National MDS Natural History Study evaluating the clinical utility of targeted...